IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
35.95
+1.61 (4.69%)
Dec 4, 2025, 4:00 PM EST - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 131 employees as of December 31, 2024. The number of employees increased by 7 or 5.65% compared to the previous year.
Employees
131
Change (1Y)
7
Growth (1Y)
5.65%
Revenue / Employee
$1,639,954
Profits / Employee
-$1,227,000
Market Cap
3.15B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 131 | 7 | 5.65% |
| Dec 31, 2023 | 124 | 21 | 20.39% |
| Dec 31, 2022 | 103 | 22 | 27.16% |
| Dec 31, 2021 | 81 | 19 | 30.65% |
| Dec 31, 2020 | 62 | 15 | 31.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IDYA News
- 2 days ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - PRNewsWire
- 6 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 9 days ago - Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away - Seeking Alpha
- 10 days ago - IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events - PRNewsWire
- 4 weeks ago - IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2025 SMID Cap Biopharma Call Series Transcript - Seeking Alpha
- 4 weeks ago - IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events - PRNewsWire